Trials / Unknown
UnknownNCT05781516
Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
A Prospective, Randomized Controlled Study to Compare the Efficacy and Safety of Baricitinib Combined With Glucocorticoid and Glucocorticoid Monotherapy in Proliferative IgG4-RD Patients With Eosinophilia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- Sponsor
- Wen Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.
Detailed description
This is a multicenter, 52-week prospective, randomized controlled study to compare the efficacy and safety of Baricitinib combined with glucocorticoid and glucocorticoid monotherapy in proliferative IgG4-RD patients with eosinophilia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisolone | Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months. |
| DRUG | Baricitinib | Oral Baricitinib 2mg daily for 12 months. |
Timeline
- Start date
- 2023-01-20
- Primary completion
- 2024-06-01
- Completion
- 2025-06-01
- First posted
- 2023-03-23
- Last updated
- 2023-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05781516. Inclusion in this directory is not an endorsement.